Enlivex Therapeutics Ltd.

Tel Aviv Stock Exchange ENLV.TA

Enlivex Therapeutics Ltd. Capital Expenditure for the year ending December 31, 2023: USD -236.00 K

Enlivex Therapeutics Ltd. Capital Expenditure is USD -236.00 K for the year ending December 31, 2023, a 97.09% change year over year. Capital expenditure is cash spent on acquiring or maintaining fixed assets, such as property, plants, and equipment (PP&E).
  • Enlivex Therapeutics Ltd. Capital Expenditure for the year ending December 31, 2022 was USD -8.12 M, a -399.82% change year over year.
  • Enlivex Therapeutics Ltd. Capital Expenditure for the year ending December 31, 2021 was USD -1.62 M, a -59.47% change year over year.
  • Enlivex Therapeutics Ltd. Capital Expenditure for the year ending December 31, 2020 was USD -1.02 M, a -427.98% change year over year.
  • Enlivex Therapeutics Ltd. Capital Expenditure for the year ending December 31, 2019 was USD -193.00 K, a 58.13% change year over year.
Key data
Date Capital Expenditure Free Cash Flow Depreciation And Amortization Deferred Income Tax
Market news
Tel Aviv Stock Exchange: ENLV.TA

Enlivex Therapeutics Ltd.

CEO Dr. Oren Hershkovitz Ph.D.
IPO Date July 22, 2019
Location Israel
Headquarters 14 Einstein Street
Employees 77
Sector Health Care
Industries
Clinical Trials Biotechnology Pharmaceuticals
Description

Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. The company has a collaboration agreement with BeiGene to evaluate the safety and efficacy of Allocetra in combination with tislelizumab, an anti-PD-1 immune checkpoint inhibitor for the treatment of patients with advanced-stage solid tumors. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.

StockViz Staff

January 16, 2025

Any question? Send us an email